APOL1 and chronic kidney disease: Nonetheless, regardless of the APOL1 risk variants, it appears that new therapies that target the NOTCH3 pathway could have a key role in preventing the development of HIV-related CKD by decreasing HIV-1 genes and inflammation in kidneys and likely other organs.